Alnylam Pharmaceuticals, Inc. vs CVS Health Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.98 (market cap $29.60B), while CVS Health Corp trades at $93.39 (market cap $119.58B). The key difference: CVS Health Corp is far larger — about 4× Alnylam Pharmaceuticals, Inc.'s market cap, and CVS Health Corp pays a 2.84% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | CVS | |
|---|---|---|
Market Cap | $29.60B | $119.58B |
Sector | Health | Health |
52-Week High | $491.22 | $110.60 |
52-Week Low | $205.48 | $65.51 |
Enterprise Value | $27.56B | $181.93B |
Dividend Yield | — | 2.84% |
Trailing returns across standard periods
Latest headlines on both assets
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →